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ABSTRACT
In total, 96 carbapenem-resistant isolates of Acinetobacter baumannii were obtained from 25 hospitals in 17
European countries. Imipenem MICs ranged from <4 to 128 mg ⁄L on retesting by Etest, with MICs
‡16 mg ⁄L being associated with the carriage of genes encoding at least one other class D carbapenemase
in addition to the intrinsic OXA-51-like enzyme. Molecular typing results obtained by random amplified
polymorphic DNA analysis, followed by pulsed-field gel electrophoresis (PFGE) of ApaI-digested
chromosomal DNA, were highly congruent, with 17 different PFGE types being delineated at a cut-off
similarity level of 85%. With few exceptions, multiple isolates from a single hospital belonged to the
same PFGE type. Seven sequence groups were identified among the 96 A. baumannii isolates, with the
majority of isolates (n = 81) belonging to the previously defined sequence groups 1 and 2, which each
included eight PFGE types. These two multinational lineages included the previously defined European
clones II and I, respectively, but the problem of resistant A. baumannii in Europe appeared not to be
confined solely to these two European clones. Rather, two broader lineages of carbapenem-resistant
A. baumannii now seem to be spreading throughout Europe.
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INTRODUCTION
Antimicrobial resistance is causing increasing
concern worldwide, with many of the major
resistance problems being caused by nosocomial
pathogens present in the hospital environment.
Intensive antibiotic use in hospitals potentiates
these resistance problems, which are further
compounded by the ever-increasing immunosup-
pression that comes with modern diagnostic and
therapeutic modalities, and the opportunities for
cross-infection that exist in modern, busy, often
over-crowded and under-staffed hospitals.
Against this background, four study groups of
the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) formulated the
ARPAC (Antibiotic Resistance, Prevention and
Control) project to investigate what measures
were being attempted to control antimicrobial
resistance among key ‘alert’ organisms causing
infections in hospitals at a pan-European level [1].
One of the key multiresistant ‘alert’ organisms
currently posing major challenges to hospitals in
Europe is Acinetobacter baumannii. This organism,
and its close relatives, can cause a wide range of
nosocomial infections, especially in immunocom-
promised patients, but their most important role
is as a cause of nosocomial pneumonia, particu-
larly in intensive care units [2–4]. Many nosoco-
mial isolates of Acinetobacter are multiresistant,
meaning that infections caused by these organ-
isms are difficult to treat, even with combination
therapy [4]. Moreover, these organisms often
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cause outbreaks of infection [2–4] and can survive
for long periods in the hospital environment, even
in dry conditions [5].
Carbapenems have been the mainstay of treat-
ment for Acinetobacter infections for the past
decade, and still remain active in many centres,
but reports of carbapenem resistance have
now accumulated worldwide [6,7]. Most recently,
significant problems have been caused by
multiresistant strains of A. baumannii in hospitals
in Europe and the USA following repatriation of
military patients from the ongoing conflict in Iraq
[8,9], with very few therapeutic options remaining
for the treatment of patients infected by such
multiresistant strains. The emergence of carbape-
nem resistance among strains of A. baumannii is
now recognised as a major problem that warrants
microbiological and epidemiological interven-
tions [10]. Accordingly, the aim of the present
study was to gain an insight into the population
structure of carbapenem-resistant strains of
A. baumannii causing nosocomial infections in
hospitals across Europe.
MATERIALS AND METHODS
Bacterial isolates
The ARPAC project [1] collected data concerning key ‘alert’
organisms, including multiresistant A. baumannii, from 169
hospitals in 32 European countries between 2001 and 2004.
Hospitals that reported encountering carbapenem-resistant
strains of Acinetobacter spp. were contacted during 2004 and
asked to submit examples of these strains where these were
still available. In total, 84 isolates of Acinetobacter were
obtained from 22 ARPAC-participating hospitals; a further 16
isolates from the same period were obtained from three non-
ARPAC hospitals to obtain a broader representation. Also
included in the study were standard reference strains of
European clones I (RUH 2034), II (RUH 134) and III (RUH
5875), defined previously by amplified fragment length poly-
morphism (AFLP) analysis [11,12] (gift of L. Dijkshoorn,
Leiden University Medical Center, The Netherlands).
Isolates were originally identified as Acinetobacter spp.
at the submitting laboratories by a variety of routine
microbiological methods. Identification of isolates as mem-
bers of the Acinetobacter calcoaceticus–A. baumannii (Acb)
complex was confirmed on receipt by tRNA spacer finger-
printing [13], followed by the use of a multiplex PCR [14] to
demonstrate the presence of a gene encoding an OXA-51-like
enzyme, which is considered to be an enzyme that is
intrinsic and unique to A. baumannii [15,16]. The same
multiplex PCR was used to simultaneously demonstrate the
presence of OXA-23-like, OXA-24-like and OXA-58-like
enzymes. All isolates were tested for susceptibility to
imipenem using Etests (AB Biodisk, Solna, Sweden) as
recommended by the manufacturer.
Molecular typing
Random amplified polymorphic DNA analysis (RAPD). Initial RAPD
analysis of the isolates was performed using primer DAF4 as
described by Grundmann et al. [17], with analysis of RAPD
products on agarose 1.5% w ⁄v gels in 1· TBE buffer (89 mM
Tris, 89 mM boric acid, 2 mM EDTA). A 100-bp DNA ladder
(GE Healthcare Life Sciences, Little Chalfont, UK) was
included as a standard for gel normalisation purposes in the
left- and right-hand lanes of each gel, and at least once every
six lanes. Following staining with ethidium bromide, the gel
images were saved as TIFF files using a GAS-9201 UVIsave
image analysis system (UVItec, Cambridge, UK). Gel analysis
was performed using BioNumerics v.2.0 (Applied Maths, Sint-
Martins-Latem, Belgium). Similarity was calculated using the
Dice coefficient with an optimisation of 0.5%, a tolerance of
1.5%, and the unweighted pair-group method using arithmetic
averages (UPGMA). It has been shown previously [18] that
good discrimination is achieved between genetically unrelated
groups of Acinetobacter spp. using a similarity cut-off value of
72%. Isolates that clustered together with a similarity of >72%
were therefore considered to belong to the same RAPD type.
Pulsed-field gel electrophoresis (PFGE). Isolates were typed by
PFGE using a method based on that described by Bannerman
et al. [19]. In brief, intact genomic DNA was prepared in
agarose plugs and then digested with ApaI (Promega, South-
ampton, UK). DNA fragments were separated on agarose
1% w ⁄v gels in 0.5· TBE buffer at 14C in a CHEF DRII
apparatus (Bio-Rad, Hemel Hempstead, UK) at 200 V, with
pulses ramped from 5 to 13 s for 20 h. An ApaI digest of
genomic DNA from A. baumannii strain RUH 2034 was
included as a standard for gel normalisation purposes in the
left- and right-hand lanes of each gel, and at least once every
six lanes. Gels were stained with ethidium bromide, saved as
TIFF files and analysed using BioNumerics v.2.0 as described
above. Isolates that clustered together with a similarity of
>85% were considered to belong to the same PFGE type.
Identification of PCR-based sequence groups
Two multiplex PCRs, designed to selectively amplify group 1
or group 2 alleles of the ompA, csuE and blaOXA-51-like genes,
were performed as described by Turton et al. [20], except that
each reaction used a Ready-to-Go PCR Bead (GE Healthcare
Life Sciences) containing pre-formulated PCR buffer, dNTPs
and Taq polymerase in a final reaction volume of 25 lL.
RESULTS
Identification of isolates
In total, the present study collected 100 Acineto-
bacter isolates from 25 hospitals in 17 European
countries (Table 1). All of these isolates were
identified as members of the Acb complex accord-
ing to tRNA spacer fingerprinting. However, this
technique has difficulty in distinguishing among
the closely related genomic species contained
within the Acb complex, and four isolates were
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revealed by PCR to lack a gene encoding an OXA-
51-like carbapenemase, which is an enzyme that is
considered to be intrinsic and unique to A. bau-
mannii [15,16]. These four isolates were therefore
not studied further.
Carbapenem resistance of isolates
Although all of the remaining 96 isolates were
considered by the submitting laboratories to be
resistant to carbapenems, Fig. 1 shows that,
according to Etests, the distribution of imipenem
MICs for these isolates varied from <4 to
128 mg ⁄L, with no clear cut-off between ‘resis-
tant’ and ‘susceptible’ isolates. As mentioned
above, each of these isolates harboured a gene
encoding an OXA-51-like class D b-lactamase;
however, the multiplex PCR used to identify the
OXA-51-like gene also revealed that 26 (92.9%) of
the 28 isolates with an imipenem MIC of
‡16 mg ⁄L (which would be regarded as resistant
according to CLSI breakpoint criteria [21]) also
harboured a gene encoding either an additional
OXA-23-like (n = 6), OXA-24-like (n = 5) or OXA-
58-like (n = 15) enzyme, compared with only
five (7.3%) (two OXA-23-like and three OXA-58-
like enzymes) of the 68 isolates with an imipenem
MIC of <16 mg ⁄L. The geographical and clonal
distribution of the isolates that produced addi-
tional OXA enzymes is shown in Table 1.
Table 1. Geographical location of
hospitals submitting carbapenem-
resistant isolates of Acinetobacter bau-
mannii (n = 96) showing clusters
according to pulsed-field gel electro-
phoresis (PFGE) and random ampli-
fied polymorphic DNA (RAPD)
analysis, and OXA-type enzymes
Country Hospital No. of isolates PFGE type RAPD types OXA enzymesa
Spain A 2 I 16 OXA-24-like
Poland B 6 II 13, 14
2 VII 4 OXA-23-like
C 6 VIIIb 6
1 XV 12
3 VII 4
D 1 VIIIb 6
1 XVIc 15 OXA-23-like
1 XVII 23
Ed 1 VIIIb 6
1 XVIc 15
1 XVII 23
F 9 XVI I5
Czech Republic G 1 III 15
Slovakia H 2 III 10
Germany I 1 IV 11 OXA-58-like
1 X 19
Je 1 XI 21 OXA-58-like
Croatia K 16 V 1, 2, 8
Norway L 1 VI 9 OXA-58-like
Bulgaria M 2 VII 1 OXA-23-like
N 5 IX 1 OXA-23-like
Slovenia O 1 VII 3 OXA-23-like
Turkey P 2 X 19, 20 OXA-58-like
Estonia Q 3 XII 24
Austria R 1 XIII 17
Portugal S 7 XIV 22 OXA-24-like
Denmark T 1 XV 12 OXA-58-like
UK U 4 XVIc 15 OXA-23-like
Greece V 5 IV 11, 13 OXA-58-like
W 2 IV 7, 18 OXA-58-like
X 2 IV 7 OXA-58-like
2 XVIc 15 OXA-23-like
The Netherlands Yd 1 X 19 OXA-23-like
aPresence of gene encoding an OXA-type carbapenemase in cluster in addition to the intrinsic OXA-51-like enzyme.
bFormed a PFGE cluster with the reference strain of European clone I [11,12].
cFormed a cluster with the reference strain of European clone II [11,12].
dOne additional isolate from this hospital lacked a gene encoding an OXA-51-like gene and was discarded.
eTwo additional isolates from this hospital lacked a gene encoding an OXA-51-like gene and were discarded.
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Fig. 1. Distribution of imipenem MICs among 96 clinical
isolates of Acinetobacter baumannii considered to be carba-
penem-resistant by 26 hospitals in 17 European countries.
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Typing of isolates by RAPD and PFGE
Initial RAPD analysis using the DAF4 primer
and a previously defined similarity cut-off value
of 72% revealed that the 96 A. baumannii iso-
lates belonged to 24 RAPD types. Subsequent
PFGE analysis based on ApaI digestion of total
chromosomal DNA revealed 17 PFGE types,
with some PFGE types encompassing more than
one RAPD type. With few exceptions (hospi-
tals B, C, D, E, I and X), multiple isolates from a
single hospital belonged to the same PFGE type
(Table 1). There were only three RAPD types
(nos 1, 13 and 15) that corresponded to more
than one PFGE type (Table 1). The reference
strain of European clone I clustered (using an
85% PFGE cut-off level) with two clinical
isolates from Poland. Similarly, the reference
strain of European clone II formed a cluster at
the 85% PFGE cut-off level with four clinical
isolates from the UK, two isolates from Poland
and two isolates from Greece (Table 1). The
reference strain of European clone III had a
PFGE profile that did not cluster with any of
the clinical isolates in the present study. Table 2
summarises the inter-relationships of PFGE and
RAPD types.
Sequence groups
Based on two multiplex PCRs designed to detect
allele variations in the ompA, csuE and blaOXA-51-
like genes, seven different sequence groups were
identified among the 96 A. baumannii isolates.
Table 2 summarises their relationship with the
PFGE and RAPD types. The majority of isolates
(n = 81) belonged to previously defined sequence
groups 1 and 2, which each included eight PFGE
types (Table 2). As described previously, these
two multinational lineages also included Euro-
pean clones II and I, respectively [20]. Sequence
group 3 contained European clone III and one
other PFGE type (one isolate). The remaining 14
isolates belonged to four other variant sequence
groups, defined according to new combinations of
amplicons obtained in the two separate multiplex
PCRs (Table 3). Interestingly, five PFGE types (IV,
X, XII, XV and XVII) were represented in more
than one sequence group (Table 2).
DISCUSSION
Of 169 European hospitals in 32 European coun-
tries that provided data to ARPAC [1], 130
reported that they had encountered carbapenem-
resistant isolates of Acinetobacter, ranging from
sporadic resistant isolates to an endemic ⁄
epidemic situation (ARPAC, unpublished data).
Of the 22 hospitals that provided isolates for the
present study, the majority were located in east-
ern, central or southeastern countries of Europe
(Table 1), which may indicate particular prob-
lems with epidemic multiresistant strains of
A. baumannii in these areas. Data concerning
carbapenem-resistant strains of A. baumannii in
these countries are scarce, but it has been reported
that such strains are prevalent in hospitals in
Greece [22] and Poland [23]. Sporadic isolates from
hospitals in countries such as Denmark, Norway
and The Netherlands may be a consequence
Table 2. Relationship between sequence groups, pulsed-
field gel electrophoresis (PFGE) types and randomly
amplified polymorphic DNA (RAPD) types for 96 clinical
isolates of Acinetobacter baumannii from European hospitals
Sequence groupa PFGE types RAPD types Geographical origin of isolates
1 (n = 30) I 16 Spain
II 13, 14 Poland
III 10, 15 Czech Republic, Slovakia
IV 11, 13, 18 Germany, Greece
X 19 Germany
XV 12 Poland
XVIb 15 Greece, Poland, UK
XVII 23 Poland
2 (n = 51) IV 7 Greece
V 1, 2, 8 Croatia
VI 9 Norway
VII 1, 3, 4 Bulgaria, Poland, Slovenia
VIIIc 6 Poland
IX 1 Bulgaria
XII 24 Estonia
XVII 5 Poland
3 (n = 1) XId 21 Germany
4 (n = 10) X 19, 20 The Netherlands, Turkey
XIV 22 Portugal
5 (n = 2) XIII 17 Austria
XV 12 Denmark
6 (n = 1) IV 7 Greece
7 (n = 1) XII 24 Estonia
aSequence groups 1, 2 and 3 correspond to those defined by Turton et al. [20].
bFormed a PFGE cluster with the reference strain of European clone II [11,12].
cFormed a PFGE cluster with the reference strain of European clone I [11,12].
dDid not form a PFGE cluster with the reference strain of European clone III [12].
Table 3. New combinations of amplicons obtained in the
multiplex PCRs used to define variant sequence groups
Variant
sequence
group
designation
Group 1 PCR Group 2 PCR
csuE
702 bp
blaOXA-51
559 bp
ompA
355 bp
csuE
580 bp
ompA
343 bp
blaOXA-51
162 bp
4 ) + + ) ) )
5 ) ) + ) ) )
6 + ) ) ) + +
7 ) ) + + ) )
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of travellers returning from countries where
resistant strains are more prevalent. The distribu-
tion of imipenem MICs for the 96 isolates of
A. baumannii varied from <4 to 128 mg ⁄L, with no
clear cut-off between ‘resistant’ and ‘susceptible’
isolates, which may indicate the existence of a
range of different resistance mechanisms.
The precise mechanism(s) of carbapenem resis-
tance in these isolates was not the focus of the
present investigation, but the study revealed that
92.9% of the isolates with an imipenem MIC of
‡16 mg ⁄L also harboured a gene encoding either
an additional OXA-23-like, OXA-24-like or OXA-
58-like enzyme, as compared with only 7.3% of
the isolates with an imipenem MIC of <16 mg ⁄L.
While the genes encoding an OXA-24-like enzyme
were confined to two molecular types from Spain
and Portugal, the genes encoding the OXA-23-like
and OXA-58-like genes were more widely distrib-
uted among a number of different types. This is
in agreement with previous reports that genes
encoding OXA-23-like and OXA-58-like
enzymes have greater mobility than genes encod-
ing OXA-24-like enzymes. In particular, OXA-58
has been associated with carbapenem resistance
in isolates of A. baumannii in Greece, southern
Europe, the Balkans and central Turkey [22,24],
while OXA-24-like enzymes (OXA-40) have been
associated particularly with isolates from the
Iberian peninsula [25,26]. However, as a general
observation, A. baumannii isolates from Europe
that exhibit higher levels of carbapenem resis-
tance seemed to express at least one other class D
OXA-type carbapenemase in addition to the
intrinsic OXA-51-like enzyme.
The primary aim of the present study was to
gain an insight into the population structure of
carbapenem-resistant isolates of A. baumannii
causing nosocomial infections in hospitals across
Europe. The present study revealed 17 PFGE
types among the 96 isolates examined, with the
majority (84%) of these belonging to two multi-
national lineages, defined on the basis of sequence
variations among different alleles of the ompA,
csuE and blaOXA-51-like genes. Previous studies of
nosocomial outbreaks of infection caused by
A. baumannii have used AFLP analysis to identify
three pan-European ‘clones’ [11,12]. Unfortu-
nately, the AFLP technique is only used routinely
in a single laboratory in The Netherlands, and it is
not clear how the results obtained by AFLP
compare with those obtained by the more widely
used reference standard technique of PFGE.
Sequence groups 1 and 2 were found to include
AFLP European clones II and I, respectively, as
also reported by Turton et al. [20], and it seems
that these two sequence groups may represent
two broader lineages of resistant A. baumannii
that are spreading in Europe. In support of this
hypothesis, previous studies have also suggested
that the problem of multiresistant A. baumannii is
not confined solely to the well-known European
clones identified by AFLP. Thus, an analysis by
AFLP of A. baumannii isolates from 46 hospitals
throughout the UK in 1999–2001 revealed the
presence of new outbreak-associated genotypes
[27], and a study of endemic A. baumannii strains
in Sofia, Bulgaria revealed that only a single
isolate belonged to a previously identified Euro-
pean AFLP clone [28].
The results obtained using the two group-
specific multiplex PCRs were remarkably congru-
ent with the PFGE results. Some PFGE types were
represented in more than one sequence group, but
this is perhaps not surprising, as the PFGE type is
based on an analysis of restriction sites through-
out the entire genome, whereas the sequence
group depends on sequence variations in the
alleles of only three genes. What is perhaps more
remarkable is the overall stability of the sequence
groups in these carbapenem-resistant isolates
from throughout Europe, which suggests that
these multinational lineages must have specific
features that contribute to their successful
dissemination and overall pathogenicity. PFGE
enabled greater discrimination within the
sequence groups, and this ‘micro-variation’ can
be used to investigate outbreaks and to compare
data among laboratories. Similarly, despite well-
known limitations, RAPD analysis produced
results that were broadly congruent with those
obtained by PFGE. With few exceptions, multiple
isolates from a single hospital belonged to the
same PFGE and RAPD types.
In conclusion, the majority (84%) of carbape-
nem-resistant isolates from European hospitals
belonged to two multinational sequence groups,
which each included eight PFGE types. Carbape-
nem resistance in these isolates was usually
associated with the expression of at least one
other OXA-type carbapenemase in addition to the
OXA-51-like enzyme that is intrinsic to A. bau-
mannii. Although the present study identified two
of the European clones defined previously on the
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basis of AFLP analysis, the problem of resistant
A. baumannii in Europe may not be confined
solely to these two AFLP clones, and two broader
lineages of resistant A. baumannii may be spread-
ing throughout Europe. Several other variant
sequence groups were identified, and comparison
of these less successful lineages with the predom-
inant sequence groups may enable new insights
into the reasons for successful dissemination
and ⁄ or pathogenicity.
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